Revenue, 2025

USD 16.38 Billion

Forecast, 2035

USD 25.68 Bilion

CAGR, 2026-2035

4.6%

Report Coverage

North America

North America Asthma and COPD Drugs Market Trends for 2026

The North America asthma and COPD drugs market size was estimated at USD 16.38 billion in 2025 and is predicted to increase from USD 17.13 billion in 2026 to approximately USD 25.68 billion by 2035, expanding at a CAGR of 4.6% from 2026 to 2035. The growing geriatric population is leading to a rise in asthma and COPD diseases in North America, increasing the use of these medications. Growing demand for biologics, increasing health awareness, R&D activities, and new product launches are also enhancing the market growth.

Key Takeaways

• The North America asthma and COPD drugs market will likely exceed USD 17.13 billion by 2026.
• Valuation is projected to hit USD 25.68 billion by 2035.
• Estimated to grow at a CAGR of 4.6% starting from 2026 to 2035.
• The global asthma and COPD drugs market is projected to grow from USD 43.10 billion in 2025 to USD 70.27 billion by 2035, at a CAGR of 5.01%.
• The U.S. held the major revenue share of 78.8% in the North America asthma and COPD drugs market in 2025.
• Canada held 21.2% share of the market in 2025 and is expected to grow at the fastest CAGR of 4.80% during the forecast period.
• By drug class type, the bronchodilators segment held a dominant revenue share of 34% of the market in 2025.
• By drug class type, the biologics segment held 13% of market share in 2025 and is expected to grow at the fastest CAGR of 8.20% during the forecast period.
• By disease type, the asthma segment held a dominant revenue share of 46% of the market in 2025.
• By disease type, the asthma-COPD overlap syndrome (ACOS) segment held 12% of market share in 2025 and is expected to grow at the fastest CAGR of 6.20% during the forecast period.
• By distribution channel type, the retail pharmacies segment held a dominant revenue share of 45% of the market in 2025.
• By distribution channel type, the online pharmacies segment held 10% of market share in 2025 and is expected to grow at the fastest CAGR of 8.10% during the forecast period.
• By end user, the hospitals segment held a dominant position in the market with a share of 39% in 2025.
• By end user, the homecare settings segment held 24% of the market in 2025 and is expected to grow at the fastest CAGR of 6.50% during the forecast period.

What are the North America Asthma and COPD Drugs?

The North America asthma and COPD drugs market was driven by increasing respiratory disease and demand for advanced drug delivery technologies. The North America asthma and COPD drugs refer to the development, production, and sales of drugs for the treatment of respiratory diseases across North America. These drugs help in improving lung function, reducing inflammation, and relieving symptoms, improving the patient's quality of life.

Why is the Use of AI Increasing in the Market?

The use of AI in the North America asthma and COPD drugs market is increasing as they help in reducing asthma attacks and COPD flare-ups. It also helps in accurate disease detection and patient monitoring, ensuring improved treatment adherence. AI is also used in the development of smart inhalers, new respiratory drugs, and personalized treatment options, as it analyzes large healthcare datasets.

Trends & Future Outlook of the Market

Expanding Adoption of Targeted Therapies

The growing health awareness and increasing incidences of asthma and COPD across North America are driving the demand for their effective treatment options. This, in turn, is increasing the adoption of targeted therapies for faster action and fewer side effects.

The Rise of New Drug Delivery Technologies

Growing technological advancements are increasing the development of advanced drug delivery solutions for the management of asthma and COPD. Smart inhalers and Bluetooth-enabled digital monitoring platforms are being developed.

Shift Towards Home Healthcare

Expansions of the telehealth platforms are promoting the shift towards home healthcare.This is driving online consultation, virtual disease management, remoted devices monitoring, and enhancing accessibility to the asthma and COPD drugs.

Key Indicators and Highlights

Segmental Insights

By Drug Class Insights

The Bronchodilators Segment Dominated the Market With 34% in 2025

The bronchodilators segment led the North America asthma and COPD drugs market with 34% share in 2025, as physicians widely prescribed bronchodilators as first-line maintenance therapy for COPD and asthma management. Strong adoption of LABA and LAMA formulations also supported their long-term disease control. Growth in the smoking-related COPD prevalence also continued to sustain its demand.

The combination drugs segment held the second-largest share of 28% of the market in 2025, as they improve adherence and reduce exacerbation frequency in moderate-to-severe patients. Triple therapy adoption is also accelerating among COPD populations. Pharmaceutical companies continue launching advanced inhaler combinations.

The anti-inflammatory drugs segment held 21% of the North America asthma and COPD drugs market share in 2025, due to increasing diagnosis of chronic inflammatory airway diseases supporting corticosteroid utilization. Clinical guidelines also continue recommending ICS therapies for persistent asthma. Generic penetration also improves accessibility across North America.

The biologics segment held 13% of the market share in 2025 and is expected to witness the fastest growth with a CAGR of 8.20% during the forecast period, due to the rising prevalence of severe eosinophilic asthma. Precision medicine and biomarker-based treatment selection also increase biologic adoption. Favorable reimbursement for specialty respiratory drugs also supports market expansion.

By Disease Type Insights

The Asthma Segment Dominated the Market With 46% in 2025

The asthma segment accounted for the highest revenue share of 46% of the North America asthma and COPD drugs market in 2025, due to growth in environmental pollution and allergen exposure, which increased asthma prevalence rates. Early diagnosis initiatives also improved treatment penetration among pediatric and adult patients. Long-term controller therapy usage continued to expand.

The COPD segment held the second-largest share of 42% of the market in 2025, as aging populations and smoking-related lung damage increase COPD incidence across North America. Frequent hospitalizations also encourage preventive maintenance therapy adoption. Growing awareness campaigns also improve disease management compliance.

The asthma-COPD overlap syndrome (ACOS) segment held 12% of the North America asthma and COPD drugs market share in 2025 and is expected to show the highest growth with a CAGR of 6.20% during the forecast period, as physicians increasingly recognize overlap syndrome as a distinct respiratory condition. Combination biologics and triple therapies also improve treatment outcomes. Advanced diagnostic approaches are also supporting earlier identification of ACOS patients.

By Distribution Channel Insights

The Retail Pharmacies Segment Dominated the Market With 45% in 2025

The retail pharmacies segment held a major revenue share of 45% of the North America asthma and COPD drugs market in 2025, driven by their strong accessibility for chronic respiratory medication refills. Broad insurance coverage also supported recurring prescription volumes. Chain pharmacy expansion also enhanced nationwide product availability.

The hospital pharmacies segment held the second-largest share of 31% of the market in 2025, as hospitals manage severe respiratory exacerbations requiring immediate drug dispensing. Growing inpatient COPD admissions also support institutional pharmacy sales. Growing specialty biologic therapies also increase hospital pharmacy utilization.

The specialty pharmacies segment held 14% of the North America asthma and COPD drugs market share in 2025, due to their efficient handling of high-cost biologics and complex respiratory therapies. Patient support programs also improve continuity of care. Growing biologic prescriptions also increase specialty dispensing demand.

The online pharmacies segment held 10% of the market share in 2025 and is expected to expand rapidly with a CAGR of 8.10% during the forecast period, driven by digital healthcare adoption, which accelerates online respiratory drug purchases. Home delivery convenience also improves medication adherence among chronic patients. E-prescription integration also supports online pharmacy growth.

By End User Insights

The Hospitals Segment Dominated the Market With 39% in 2025

The hospitals segment contributed the biggest revenue share of 39% of the North America asthma and COPD drugs market in 2025, as they are considered the primary treatment centers for acute asthma and COPD exacerbations. Growth in emergency admissions also sustained respiratory drug utilization. Advanced respiratory care infrastructure also supported therapeutic demand.

The specialty respiratory clinics segment held the second-largest share of 27% of the market in 2025, as specialized clinics increasingly manage severe and chronic respiratory disorders. Pulmonologists are adopting biologics and advanced inhalation therapies rapidly. Improved outpatient respiratory monitoring also supports clinic growth.

The homecare settings segment held 24% of the North America asthma and COPD drugs market share in 2025 and is expected to gain the highest share with a CAGR of 6.50% during the forecast period, due to growing chronic disease burden and aging populations. Portable nebulizers and inhalers also improve self-administration. Telehealth integration also enhances remote respiratory care.

The ambulatory surgical centers segment held 10% of the market share in 2025, as they support respiratory diagnostics and outpatient therapeutic procedures. Increasing minimally invasive pulmonary interventions sustains drug demand. Cost-effective outpatient care models also support market expansion.

Global Asthma And COPD Drugs Market

The global asthma and COPD drugs market size was calculated at USD 43.10 billion in 2025, to reach USD 45.26 billion in 2026 is expected to be worth USD 70.27 billion by 2035, expanding at a CAGR of 5.01% from 2026 to 2035.

Regional Insights

Growth in Disease Burden Drives North America

The North America asthma and COPD drugs market showed considerable growth, due to the growth in the asthma and COPD cases. High smoking rates and a geriatric population also contributed to their growth, which increased the use of various drugs. A rise in health awareness and R&D activities also enhanced the market growth.

U.S. Market Trends

The U.S. held the major revenue share of 78.8% in the North America asthma and COPD drugs market in 2025, due to large COPD and asthma patient pools, which supported consistent prescription volumes. High biologic adoption also promoted specialty respiratory therapy growth. Extensive insurance coverage also improved treatment accessibility.

Canada Market Trends

Canada held 21.2% share of the in 2025 and is expected to grow at the fastest CAGR of 4.80% during the forecast period, due to public healthcare coverage, which supports widespread respiratory treatment utilization. Rising pollution-related asthma cases are also increasing inhaler demand. Government awareness programs also improve disease diagnosis rates.

Market Value Chain

R&D

• The R&D of the North America asthma and COPD drugs focuses on the development of targeted biologics, long-acting injectables, and anti-inflammatory rescue therapies.
• Key players: GlaxoSmithKline, Regeneron Pharmaceuticals, Sanofi.

Clinical Trials and Regulatory Approvals

• The drug efficacy, device performance, manufacturing quality, and patient safety are evaluated in the clinical trials and regulatory approvals of the asthma and COPD drugs in North America.
• Key players: GlaxoSmithKline, Regeneron Pharmaceuticals, Sanofi.

Patient Support and Services

• The financial aid, nurse training, and copay cards are provided in the patient support and services of the asthma and COPD drugs in North America.
• Key players: GlaxoSmithKline, Regeneron Pharmaceuticals, Sanofi.

Who are the Market Top Vendors and What are Their Offerings?

SWOT Analysis

Strengths

• The asthma and COPD drugs help in enhancing breathing and lung function, which increases their adoption across North America.
• It also helps in reducing the attacks and flare-ups, which increases their use.
• Their long-term control and fast action also increase their demand.
• Their widespread availability also increases their adoption rates.

Weaknesses

• High cost associated with the advanced asthma and COPD drugs acts as a major weakness in the North America asthma and COPD drugs market, limiting their use.
• Poor patient adherence also reduces their use.

Opportunities

• Increasing adoption of advanced biologic therapies promotes the adoption of asthma and COPD drugs.
• Increasing asthma and COPD burden across North America is increasing their demand.
• Growing health awareness also drives the demand for smart inhalers and new combination therapies.
• Expanding telehealth platforms also increases their accessibility and use.

Threats

• High cost associated with the raw material and production reduces the advancement of asthma and COPD drugs.
• Stringent regulatory compliance, where their failure leads to product recalls or bans, also limits their innovations.

What are the Major Recent Developments in the Market?

• In May 2026, to discover a new approach to reduce COPD flare-ups, the COPD-OMA trial was launched by the American Lung Association (ALA). Omalizumab (Xolair), an already FDA-approved drug for asthma and allergic diseases, will be examined in this trial with the help of the Airways Clinical Research Centers (ACRC).
• In April 2026, fixed-dose triple-combination therapy BREZTRI Aerosphere® (budesonide/glycopyrrolate/formoterol fumarate), which is a single-inhaler combining the efficacy of corticosteroid/long-acting beta2-agonist with a long-acting muscarinic antagonist, was approved in the US for the maintenance treatment of asthma in adult and pediatric patients. In 2020, it was approved for the treatment of chronic obstructive pulmonary disease (COPD) in adults.

Segments Covered in the Report

By Drug Class

• Bronchodilators
  • Beta2-Agonists
    • Short-Acting Beta2-Agonists (SABA)
    • Long-Acting Beta2-Agonists (LABA)
  • Anticholinergics
    • Short-Acting Muscarinic Antagonists (SAMA)
    • Long-Acting Muscarinic Antagonists (LAMA)
  • Methylxanthines
• Anti-Inflammatory Drugs
  • Inhaled Corticosteroids (ICS)
  • Oral Corticosteroids
  • Leukotriene Modifiers
  • PDE-4 Inhibitors
• Combination Drugs
  • ICS/LABA Combinations
  • LABA/LAMA Combinations
  • Triple Combination Therapy (ICS/LABA/LAMA)
• Biologics
  • Anti-IgE Therapy
  • Anti-IL5 Therapy
  • Anti-IL4/IL13 Therapy
  • TSLP Inhibitors
• Other Drugs
  • Mast Cell Stabilizers
  • Mucolytics
  • Antibiotic Adjuncts

By Disease Type

• Asthma
  • Allergic Asthma
  • Non-Allergic Asthma
  • Severe Asthma
  • Occupational Asthma
• COPD
  • Chronic Bronchitis
  • Emphysema
  • Refractory COPD
• Asthma-COPD Overlap Syndrome (ACOS)

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies

By End User

• Hospitals
• Specialty Respiratory Clinics
• Homecare Settings
• Ambulatory Surgical Centers

By Route of Administration

• Inhalation
  • Metered Dose Inhalers (MDIs)
  • Dry Powder Inhalers (DPIs)
  • Nebulizers
  • Soft Mist Inhalers
• Oral
• Injectable

By Prescription Type

• Prescription Drugs
• Over-the-Counter Drugs

By Region

• North America
  • U.S.
  • Canada
  • Mexico
  • Rest of North America